CHU Henri MONDOR
Service UROLOGIE
Tel: 01 01 01 01 01
Prendre rendez-vous
Notre chaine Youtube
Facebook du service
Intranet
Voir le profil d'Urologie Mondor sur LinkedIn

rendez vous en ligne
 
Modifié le : 12 Février, 2016
Par: WebMaster
Accueil » Qui sommes nous ? » Equipe médicale » Pr de la Taille

Professeur Alexandre DE LA TAILLE

Prendre rendez-vous en ligne

Voir le profil de András Hoznek sur LinkedIn

Nom Alexandre de la TAILLE
Statut Praticien Hospitalier, Professeur des Universités
Spécialité Chirurgie robotique, tumeurs de prostate, cancer du rein, adénome de prostate, troubles mictionnels
Secrétariat 01 49 81 25 54
Fax 01 49 81 25 52
E-mail adelataille@hotmail.com
Recherche

Directeur équipe INSERMU955Eq07
Recherche translationnelle en oncourologie
Cancer de prostate, échappement hormonal

  Consultations
Lundi
Mardi
Mercredi
Jeudi
Vendredi
Samedi
Matin
- Public
-
Public
-
-
Après-midi
-
Privée
-
Public
-
-

Pour prendre un rendez-vous en consultation publique : 01 49 81 25 57 

Pour une consultation en rendez vous privé : 01 49 81 25 54 ou par email : catherine.cabrera@hmn.aphp.fr 

Rendez vous par le site Doctolib

 

  • Curriculum Vitae
  • Publications

Alexandre de la Taille, MD, PhD.                                                            

DOB 2/17/68
Professor in Urology
CHU Mondor, Dpt Urology, Créteil, France           

Positions

Chairman of Urology Department, CHU Mondor, Assistance Publique des Hopitaux de Paris, Créteil, France
Head of INSERM Research Team on Translational Research in Oncogenesis (INSERMU955Eq07), University Paris 12, France

Diploma

PhD Thesis in Dec 2000 - MD Thesis in Sept 2000
Research Fellowship (Columbia University, New York-USA, Nov 1997 - Oct 1999)
Research Director: Dr Ralph Buttyan
Department of Urology, Columbia-Presbyterian Medical Center of the City of New York, Pr. CA Olsson
Certificates of Laparoscopy, Andrology, Statistics, Abdo-Pelvic Anatomy, Urodynamic

Awards

Matula Crystal Award – European Association of Urology 2006 Thesis Award EAU 2001 – Sanofi-synthelabo - "Biomarkers of apoptosis in prostate cancer." First Prize AUA/Circon-ACMI Essay Contest 1999 "Cadherin T6, a novel cadherin-family protein involved in the acquisition of therapeutic resistance by prostate cancer cells."

Grants

Industrial grants: Pierre Fabre Medicament, Takeda, BMS, Ipsen
Institutional grants: ARTP, AFU, Ligue Contre le Cancer,ARC, PF7

Responsibilities

Member of the Conseil d’Administration de l’Association Francaise d’Urologie
Co-Editor in Chief of World Journal of Urology (IF2.8)
Member of Scientific Office of the European Association of Urology
President of Association for Research in Prostate Diseases (www.artp.org)
Reviewer for: Eur Urol, J Urol, Urology, Cancer Control, Cancer Detection and Prevention, WJU
Head of Robotic Program in Urology in CHU Mondor
Proctoring for Intuitive Surgical for surgery on prostate and kidney using DaVinci systems
Principal investigator for several studies including Triptocare, PCA3, PhiPSA, Terrain studies, Tak700 studies
Trained for Good Clinical Practices for clinical trials

Active Collaborations

Mark Rubin, Pathologist, Cornell University, NYC, USA
Ralph Buttyan, PhD, Vancouver, Canada
Jack Schalken, PhD, Nijmegen, Pays Bas

 

377 articles in pubmed -  12 book chapters
 >500 communications in national and international meetings

 

-“Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.  Ploussard G, Nicolaiew N, Mongiat-Artus P, Terry S, Allory Y, Vacherot F, Abbou CC, Desgrandchamps F, Salomon L, de la Taille A. Prostate Cancer Prostatic Dis. 2014 Feb 11.
-“Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomy. Ploussard G, Drouin SJ, Rode J, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.  World J Urol. 2014 Jan 21.
-“Comment on "Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study" de la Taille A World J Urol. 2014 Jan 11.
-“Multicenter European External Validation of a Prostate Health Index-based Nomogram for Predicting Prostate Cancer at Extended Biopsy. Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Fossati N, Lista G, Larcher A, Abrate A, Mistretta A, Bini V, Redorta JP, Graefen M, Guazzoni G. Eur Urol. 2013 Dec 16. pii: S0302-2838(13)01326-2.
-“ [Corticotherapy in castration-resistant prostate cancer].  Lebdai S, Branchereau J, Robert G, de la Taille A, Bouchaert P. Prog Urol. 2013 Oct;23 Suppl 1:S23-33.
-“ [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer]. Ripert T, Crouzet S, Ploussard G, de la Taille A, Robert G. Prog Urol. 2013 Oct;23 Suppl 1:S16-22.
-“Evaluation of urinary symptoms in patients with post-prostatectomy urinary incontinence treated with the male sling TOMS. Yiou R, Loche CM, Lingombet O, Abbou C, Salomon L, de la Taille A, Audureau E.  Neurourol Urodyn. 2013 Oct 19.
-“PI3K/AKT pathway activation in bladder carcinogenesis. Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. Int J Cancer. 2013 Oct 7.
-“Controversies on individualized prostate cancer care: gaps in current practice. Joniau S, Pfister D, de la Taille A, Gaboardi F, Thompson A, Ribal MJ. Ther Adv Urol. 2013 Oct;5(5):233-44
-“Prostate biopsies: let's move forward. Ploussard G, de la Taille A Eur Urol. 2013 Dec;64(6):893-4.
-“Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. Hollande C, Colin P, de La Motte Rouge T, Audenet F, Yates DR, Phé V, Ouzzane A, Droupy S, Ruffion A, de la Taille A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano JP, Khayat D, Bitker MO, Rouprêt M; French Collaborative National Working-Group on UTUC. BJU Int. 2013 Jun 17.
-“Concomitant High-Grade Prostatic Intraepithelial Neoplasia Is Associated with Good Prognosis Factors and Oncologic Outcome after Radical Prostatectomy. Ingels A, Ploussard G, Allory Y, Abbou C, de la Taille A, Salomon LUrol Int. 2013 Aug 1
-“Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. Masson-Lecomte A, Colin P, Bozzini G, Nison L, de la Taille A, Comperat E, Zerbib M, Rozet F, Cathelineau X, Valeri A, Ruffion A, Guy L, Droupy S, Cussenot O, Rouprêt M. World J Urol. 2013 Aug 2.
-“Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: Epidemiological, bacteria and treatment patterns from a 4-year prospective study. Campeggi A, Ouzaid I, Xylinas E, Lesprit P, Hoznek A, Vordos D, Abbou CC, Salomon L, de la Taille A. Int J Urol. 2014 Feb;21(2):152-5.
-“Predictive factors of complications after robot-assisted laparoscopic partial nephrectomy: a retrospective multicentre study. Mathieu R, Verhoest G, Droupy S, de la Taille A, Bruyere F, Doumerc N, Rischmann P, Vaessen C, Roupret M, Bensalah K.  BJU Int. 2013 Aug;112(4):E283-9.
-“Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.  BJU Int. 2013 Aug;112(3):313-21.
-“Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F. Neoplasia. 2013 Jul;15(7):761-72.
-“Patient selection and pathological outcomes using currently available active surveillance criteria. El Hajj A, Ploussard G, de la Taille A, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L.  BJU Int. 2013 Aug;112(4):471-7.
-“ [Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease]. Masson-Lecomte A, Vordos D, Yiou R, Allory Y, Abbou C, de la Taille A, Salomon L.  Prog Urol. 2013 Jun;23(7):456-63.
-“Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. Hurel S, Rouprêt M, Ouzzane A, Rozet F, Xylinas E, Zerbib M, Berod AA, Ruffion A, Adam E, Cussenot O, Houlgatte A, Phé V, Nouhaud FX, Bensadoun H, Delage F, Guillotreau J, Guy L, Karsenty G, de la Taille A, Colin P; French Collaborative National Database on UTUC.  BJU Int. 2013 Jun;111(8):1199-207.
-“Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Ploussard G, Briganti A, de la Taille A, Haese A, Heidenreich A, Menon M, Sulser T, Tewari AK, Eastham JA. Eur Urol. 2014 Jan;65(1):7-16.
-“Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salomon L, de la Taille A Urology. 2012 Sep;80(3):576-84.
-“Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK. Eur Urol. 2012 Jul 20.
-“Prospective Evaluation of an Extended 21-Core Biopsy Scheme as Initial Prostate Cancer Diagnostic Strategy. Ploussard G, Nicolaiew N, Marchand C, Terry S, Vacherot F, Vordos D, Allory Y, Abbou CC, Salomon L, de la Taille A Eur Urol. 2012 Jun 9
-“A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA. Masson-Lecomte A, Guy L, Pedron P, Bruyere F, Rouprêt M, Nsabimbona B, Dahan M, Hoffman P, Salomon L, Vordos D, Hoznek A, Le Corvoisier P, Morel P, Abbou C, de la Taille A World J Urol. 2012 Apr 15.
-“Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Cancer Discov. 2011 Nov;1(6):487-95
-“The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, Forgues A, Robert G, Vacherot F, Loric S, Allory Y, Ruffion A, de la Taille A BJU Int. 2012 Jul;110(1):43-9.
-“Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells. Sirab N, Terry S, Giton F, Caradec J, Chimingqi M, Moutereau S, Vacherot F, de la Taille A, Kouyoumdjian JC, Loric S.  Int J Cancer. 2012 Sep 15;131(6):1297-306.
-“The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Ploussard G, de la Taille A, Bayoud Y, Durand X, Terry S, Xylinas E, Allory Y, Vacherot F, Abbou CC, Salomon L. Eur Urol. 2012 Feb;61(2):356-62.
-“Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: Trifecta rate of achieving continence, potency and cancer control. Xylinas E, Durand X, Ploussard G, Campeggi A, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L. Urol Oncol. 2011 Jun 28.
-“Kidney cancer pathology in the new context of targeted therapy. Allory Y, Culine S, de la Taille A . Pathobiology. 2011;78(2):90-8.
-“A Novel Multiplex Assay Combining Autoantibodies Plus PSA Has Potential Implications for Classification of Prostate Cancer from Non-malignant Cases. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao JY, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. J Transl Med. 2011 Apr 19;9(1):43.
-“Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A. J Urol. 2011 Apr 13.
-“Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Robert G, Smit F, Hessels D, Jannink S, Karthaus HF, Aalders T, Jansen K, de la Taille A, Mulders PF, Schalken JA. Prostate. 2011 Mar 28.
-“Progensa™ PCA3 test for prostate cancer. Durand X, Moutereau S, Xylinas E, de la Taille A. Expert Rev Mol Diagn. 2011 Mar;11(2):137-44.
-“Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F, de la Taille A. Eur Urol. 2011 Mar;59(3):422-9.
-“Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A. BJU Int. 2011 May;107(9):1400-3.
-“Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Robert G, Descazeaud A, de la Taille A. Curr Opin Urol. 2011 Jan;21(1):42-8.
-“Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A. Cancer Res. 2010 Nov 15;70(22):9253-64
-“Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. Ploussard G, Xylinas E, Durand X, Ouzaïd I, Allory Y, Bouanane M, Abbou CC, Salomon L, de la Taille A. BJU Int. 2010 Dec 22.
-“Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la Taille A, Buttyan R Mol Cancer. 2010 Apr 26;9:89.
-“Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de la Taille A, Menashi S, Calvo F, Mourah S.PLoS One. 2010 May 19;5(5):e10715.
-“Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A.World J Urol. 2010 Jun 25
-“The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? Ploussard G, Haese A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA, de la Taille A.BJU Int. 2010 Mar 1
-“Intrafascial nerve-sparing radical prostatectomy with a laparoscopic robot-assisted extraperitoneal approach: early oncological and functional results.Xylinas E, Ploussard G, Salomon L, Paul A, Gillion N, Laet KD, Vordos D, Hoznek A, Abbou CC, de la Taille A. J Endourol. 2010 Apr;24(4):577-82.
-“Urine biomarkers in prostate cancer. Ploussard G, de la Taille A. Nat Rev Urol. 2010 Feb;7(2):101
-“Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A. J Urol. 2010 Feb;183(2):539-44.
-“Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram”
Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A. Eur Urol. 2009 Mar 13.
-“SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation-Specific Fusion Transcript in Prostate Cancer”
Rickman DS, Pflueger D, Moss B, Vandoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA. Cancer Res. 2009 Mar 17.
-“Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma”
Zini L, Patard JJ, Capitanio U, Crepel M, de la Taille A, Tostain J, Ficarra V, Bernhard JC, Ferrière JM, Pfister C, Villers A, Montorsi F, Karakiewicz PI. BJU Int. 2009 Apr;103(7):894-8.
-“Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review”
Descazeaud A, Robert G, Azzousi AR, Ballereau C, Lukacs B, Haillot O, Dumonceau O, Devonec M, Fourmarier M, Saussine C, de la Taille A; French Association of Urology. BJU Int. 2008 Dec 22.
-“BPH gene expression profile associated to prostate gland volume”
Descazeaud A, Rubin MA, Hofer M, Setlur S, Nikolaief N, Vacherot F, Soyeux P, Kheuang L, Abbou CC, Allory Y,
de la Taille A. Diagn Mol Pathol. 2008 Dec;17(4):207-13.
-“Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy. “
Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA Eur Urol. 2008 Jun 26.
-“Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy. “
Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A. Eur Urol. 2008 Jun 23.
-“Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy.“ Cindolo L, Chiodini P, Gallo C, Ficarra V, Schips L, Tostain J, de la Taille A, Artibani W, Patard JJ. Cancer. 2008 Jul 1;113(1):65-71.
-“Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays.”
Burchardt M, Engers R, Müller M, Burchardt T, Willers R, Epstein JI, Ackermann R, Gabbert HE, de la Taille A, Rubin MA. J Cancer Res Clin Oncol. 2008 Apr 8.
-“Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa).”
Giton F, de la Taille A, Allory Y, Hervé Galons, Francis Vacherot, Pascale Soyeux, Claude Clément Abbou, Sylvain Loric, Olivier Cussenot, Jean-Pierre Raynaud, Jean Fiet. J Steroid Biochemistry  Mol Biology 2007
-“Progensa PCA3 test for prostate cancer detection” de la Taille A. Expert Rev Mol Diagn. 2007 Sep;7(5):491-7
-“The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?”
Paule B, Terry S, Kheuang L., Soyeux P, Vacherot F, de la Taille A,,. World J Urol 2007 Oct;25(5):477-489.
-“Multi-institutional validation of a new renal cancer-specific survival nomogram. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, de la Taille A,,, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJJ Clin Oncol. 2007 Apr 10;25(11):1316-22.
-“Extended 21-Sample Needle Biopsy Protocol for Diagnosis of Prostate Cancer in 1000 Consecutive Patients.” Guichard G, Larre S, Gallina A, Lazar A, Faucon H, Chemama S, Allory Y, Patard JJ, Vordos D, Hoznek A, Yiou R, Salomon L, Abbou CC, de la Taille A,  Eur Urol. 2007
-“Management of non-complicated BPH: proposition of a renewed decision tree.”
Desgrandchamps F, de la Taille A,,, Azzouzi AR, Fourmarier M, Haillot O, Lukacs B, Saussine C World J Urol. 2006 May 18
-“Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen.”
Descazeaud A, Rubin M, Chemama S, Larre S, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Chopin D, Abbou C, de la Taille A, World J Urol. 2006 Nov 7
-“Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.”
Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A,, Benson MC, Guo Y, Buttyan R. Oncogene. 2006 Jul 13;25(30):4256.
-“Protocadherin-PC promotes androgen-independent prostate cancer cell growth.” Terry S, Queires L, Gil-Diez-de-Medina S, Chen MW, de la Taille A,, Allory Y, Tran PL, Abbou CC, Buttyan R, Vacherot F. Prostate. 2006 Jul 1;66(10):1100-13.
-“BPH management at the turn of the twenty-first century: evolution or revolution.”
de la Taille A,, Desgrandchamps F. World J Urol. 2006 Jun 21
-“Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system.” Descazeaud A, de la Taille A,,  Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA.Prostate. 2006
-“Polyphenols purified from the Brazilian aroeira plant (Schinus terebinthifolius, Raddi) induce apoptotic and autophagic cell death of DU145 cells.” Queires LC, Fauvel-Lafetve F, Terry S de la Taille A,, Kouyoumdjian JC, Chopin DK, Vacherot F, Rodrigues LE, Crepin M.Anticancer Res. 2006 Jan-Feb;26(1A):379-87. 
-“Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.” Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A,, Benson MC, Guo Y, Buttyan R. Oncogene. 2006 Feb 13;
-“The Effects of Long Term Finasteride Treatment on Prostate Cancer Morphology and Clinical Outcome?"
Rubin MA, Allory Y, Molinié V, Leroy X, Faucon H, Vacherot F, Huang W, Kuten A, Salomon L, Abbou, Cussenot O, de la Taille A,. Urology. 2005 Nov;66(5):930-4.
-“What Information are Urologists Extracting from Prostate Needle Biopsy Reports and What do They Need for Clinical Management of Prostate Cancer?" Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C de la Taille A,. Eur Urol. 2005 Dec;48(6):911-5.
-“Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer." Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC de la Taille A, BJU Int. 2004 Sep;94(4):524-7.
-“Evaluation of the interobserver reproducibility of gleason grading of prostatic adenocarcinoma using tissue microarrays." de la Taille A,,  Viellefond A, Berger N, Boucher E, De Fromont M, Fondimare A, Molinie V V, Piron D, Sibony M, Staroz F, Triller M, Peltier E, Thiounn N, Rubin MA. Am J of Path 2003 May;34(5):444-449.
-“Beta-catenin-related anomalies in apoptosis resistant and hormone refractory prostate cancer cells." de la Taille A,, Rubin MA., Chen MW., Vacherot V., De Medina SG., Burchardt M., Buttyan R., Chopin DK, Clin Cancer Res  2003 May;9(5):1801-1807.
-“Intermittent androgen suppression in patients with prostate cancer. de la Taille A,, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA, Debré B. BJU Int. 2003 Jan;91(1):18-22.
-“The emergence of protocadherin-PC expression during the acquisition of apoptosis resistance by prostate cancer cells." de la Taille A,,.*, Chen MW.*, Vacherot V.*, Gil-Diez S., Shen R., Friedman R., Burchardt M., Chopin DK., Buttyan R. [* Premiers auteurs] Oncogene. 2002 Nov 7;21(51):7861-71.

 

Service d'urologie
Chef de service : Alexandre de la Taille
51 Av. du Ml. de Lattre de Tassigny 94010 Créteil France
Tél. : +33(0)1 49 81 25 51